Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.
Capdevila J, Hernando J, Teule A, Lopez C, Garcia-Carbonero R, Benavent M, Custodio A, Garcia-Alvarez A, Cubillo A, Alonso V, Carmona-Bayonas A, Alonso-Gordoa T, Crespo G, Jimenez-Fonseca P, Blanco M, Viudez A, La Casta A, Sevilla I, Segura A, Llanos M, Landolfi S, Nuciforo P, Manzano JL.
Capdevila J, et al. Among authors: sevilla i.
Nat Commun. 2023 May 23;14(1):2973. doi: 10.1038/s41467-023-38611-5.
Nat Commun. 2023.
PMID: 37221181
Free PMC article.
Clinical Trial.